Targeted drug therapy for NET included molecules such as Everolimus and Sunitinib. The targeted therapies are in greater demand as they are efficient in impeding the growth of cancer by targeting the specified molecules that are involved in the growth of cancer. The key advantage of targeted drug therapies is lesser side effects in comparison to chemotherapy. However, some patients are immune to radiation therapy and surgeries, therefore Somatostatin analogues such as Lu-Dotatate and Octreotide remain as an alternative therapy in this case.
The incidence rate in the U.S. for gastrointestinal neuroendocrine neoplasms was about 1.4 cases per 100,000. The healthcare infrastructure in terms of diagnostic centers and drug clearance process through USFDA is very efficient even in case of asymptomatic NET. The rising incidence rate for NET in Europe especially in case of pancreatic NET has a significant impact on the NET drug market. The European Medical Agency provides a supportive regulatory environment. In case of Asia Pacific, the incident rate for NET was 1.5 per 100,000 people. The healthcare infrastructure in APAC is emerging. There has been a significant increase in cancer specialized diagnostic centers and emerging treatment options are expected to boost the NET drugs market during the forecast period of 2021 to 2029.
The report covers the NET treatment market that includes market dynamics and market revenues for 2019 to 2029 across geographies that are segmented as follows:
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of LATAM
Middle East and Africa
- GCC
- Rest of Middle East and Africa
The report also segments the market by drug class as below – each segment covers key market segment, dynamics, and market estimation for each geographic segment for the period of 2019 to 2029.
- mTOR protein inhibitors (Everolimus)
- Tyrosine kinase 3 inhibitors (Sunitinib)
- Somatostatin receptor antagonists (Lu-Dotatate)
- Growth hormone releasing factor antagonists (Lanreotide)
- Somatostatin receptor agonists (Octreotide)
- Pipeline Analysis
- Phase III Drugs
- Vandetanib
- Fotemustine and Ipilimumab
- 177Lu-edotreotide PRRT
- Sulfatinib
- Tabular Representation of Phase II and I drugs
The report contains a detailed analysis of key market players such as Advanced Accelerator Applications, Novartis AG, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Ispen. The competitive analysis includes basic profiling, financial performance, product portfolio, pipeline products, recent developments that include strategic partnerships, R&D investment, acquisitions, joint ventures and other key information.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Neuroendocrine Tumor Treatment Market Portraiture
2.1.1. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019 (Value %)
2.1.2. Global Neuroendocrine Tumor Treatment Market, by Geography, 2019 (Value %)
2.1.3. Impact of covid 19
Chapter 3. Neuroendocrine Tumor Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Neuroendocrine Tumor Epidemiology Data (Prevalence & Incidence)
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography
3.7. Top 3 Countries: Global Neuroendocrine Tumor Treatment Market, 2019-2029 (US$ Mn)
3.8. Competitive Landscape: Global Neuroendocrine Tumor Treatment Market, by Key Players, 2019-2029(US$ Mn)
Chapter 4. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019
4.3. mTOR protein inhibitors (Everolimus)
4.4. Tyrosine kinase 3 inhibitors (Sunitinib)
4.5. Somatostatin receptor antagonists (Lu-Dotatate)
4.6. Growth hormone releasing factor antagonists (Lanreotide)
4.7. Somatostatin receptor agonists (Octreotide)
4.8. Pipeline Analysis
4.8.1. Phase III Drugs
4.8.1.1. Vandetanib
4.8.1.2. Fotemustine and Ipilimumab
4.8.1.3. 177Lu-edotreotide PRRT
4.8.1.4. Sulfatinib
4.8.2. Tabular Representation of Phase II and I Drugs
Chapter 5. Global Neuroendocrine Tumor Treatment Market, by Geography, 2019-2029(US$ Mn)
5.1. Overview
5.2. North America Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.2.1. North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
5.2.2. North America Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.3.1. Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
5.3.2. Europe Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.4.1. Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
5.4.2. Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.5.1. Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
5.5.2. Latin America Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.6.1. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
5.6.2. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Region, 2019-2029(US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of Middle East and Africa
Chapter 6. Company Profiles
6.1. Advanced Accelerator Applications
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Dauntless Pharmaceuticals, Inc.
6.3. Exelixis, Inc.
6.4. Hutchinson Medipharma Limited
6.5. Ispen
6.6. Novartis AG
6.7. Progenics Pharmaceuticals, Inc.
6.8. Tarveda Therapeutics
List of Figures
Figure 1 Neuroendocrine Tumor Treatment: Market Segmentation
Figure 2 Global Neuroendocrine Tumor Treatment Market Share, by Drug Class, 2019 (Value %)
Figure 3 Global Neuroendocrine Tumor Treatment Market Share, by Geography, 2019 (Value %)
Figure 4 Attractive Investment Proposition, by Geography
Figure 5 Market Competition Landscape, by Key Players, 2019
Figure 6 Global Everolimus Drug Market for Neuroendocrine Tumor Treatment, 2019-2029(US$ Mn)
Figure 7 Global Sunitinib Drug Market for Neuroendocrine Tumor Treatment, 2019-2029(US$ Mn)
Figure 8 Global Lu-Dotatate Drug Market for Neuroendocrine Tumor Treatment, 2019-2029(US$ Mn)
Figure 9 Global Lanreotide Drug Market for Neuroendocrine Tumor Treatment, 2019-2029(US$ Mn)
Figure 10 Global Octreotide Drug Market for Neuroendocrine Tumor Treatment, 2019-2029(US$ Mn)
Figure 11 U.S. Neuroendocrine Tumor Treatment Market, 2019– 2025 (US$ Mn)
Figure 12 Canada Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 13 U.K. Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 14 Germany Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 15 Rest of Europe Neuroendocrine Tumor Treatment Market, 2019– 2025 (US$ Mn)
Figure 16 Japan Neuroendocrine Tumor Treatment Market, 2019– 2025 (US$ Mn)
Figure 17 China Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 18 India Neuroendocrine Tumor Treatment Market, 2019– 2025 (US$ Mn)
Figure 19 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 20 Brazil Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 21 Mexico Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 22 Rest of Latin America Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 23 GCC Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
Figure 24 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market, 2019-2029(US$ Mn)
List of Tables
Table 1 Global Neuroendocrine Tumor Treatment Market Portraiture
Table 2 Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 3 Global Neuroendocrine Tumor Treatment Market, by Geography, 2019-2029(US$ Mn)
Table 4 North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 5 North America Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
Table 6 Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 7 Europe Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
Table 8 Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 9 Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
Table 10 Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 11 Latin America Neuroendocrine Tumor Treatment Market, by Country, 2019-2029(US$ Mn)
Table 12 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029(US$ Mn)
Table 13 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Region, 2019-2029(US$ Mn)
Table 14 Advanced Accelerator Applications: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 15 Dauntless Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 16 Exelixis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 17 Hutchinson Medipharma Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 18 Ispen: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 19 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 20 Progenics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 21 Tarveda Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Companies Mentioned
- Advanced Accelerator Applications
- Novartis AG
- Progenics Pharmaceuticals Inc.
- Tarveda Therapeutics
- Dauntless Pharmaceuticals Inc.
- Exelixis Inc.
- Hutchinson Medipharma Limited
- Ispen
